Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

INBX

Inhibrx Biosciences Inc

Feb 13 • 04:00PM ET

75.80

-6.31 -7.68 %

Healthcare • Biotechnology • USA • NASD

Peers: BPMC ARVN ONC PTCT EXEL PBYI ADAP KPTI IGMS

| Held by: VTI IWM XBI VXF IWN IBB FESM VTWO DWAS KOMP

Index	RUT	P/E	-	EPS (ttm)	-10.24	Insider Own	29.92%	Shs Outstand	14.50M	Perf Week	-9.67%
Market Cap	1.10B	Forward P/E	-	EPS next Y	-4.76	Insider Trans	-7.44%	Shs Float	10.19M	Perf Month	-0.17%
Enterprise Value	1.06B	PEG	-	EPS next Q	-2.08	Inst Own	65.01%	Short Float	17.06%	Perf Quarter	3.38%
Income	-155.09M	P/S	787.44	EPS this Y	-108.00%	Inst Trans	4.61%	Short Ratio	7.52	Perf Half Y	216.62%
Sales	1.40M	P/B	29.84	EPS next Y	47.17%	ROA	-77.54%	Short Interest	1.74M	Perf YTD	-4.05%
Book/sh	2.54	P/C	7.20	EPS next 5Y	-	ROE	-144.07%	52W High	94.57 -19.84%	Perf Year	476.86%
Cash/sh	10.53	P/FCF	-	EPS past 3/5Y	- -	ROIC	-109.61%	52W Low	10.81 601.53%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-69.79% -	Gross Margin	-86.29%	Volatility	7.73% 6.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	754.46	EPS Y/Y TTM	-109.03%	Oper. Margin	-11002.14%	ATR (14)	5.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.49	Sales Y/Y TTM	-19.26%	Profit Margin	-11077.57%	RSI (14)	45.06	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.49	EPS Q/Q	24.83%	SMA20	-3.30%	Beta	1.36	Target Price	12.00
Payout	0.00%	Debt/Eq	2.90	Sales Q/Q	-	SMA50	-4.77%	Rel Volume	0.59	Prev Close	82.11
Employees	161	LT Debt/Eq	2.84	Earnings	Nov 14 BMO	SMA200	72.07%	Avg Volume	231.05K	Price	75.80
IPO	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-32.56% -	Trades		Volume	137,472	Change	-7.68%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	JMP Securities	Mkt Perform

Dec-28-25 10:05AM	Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts (Insider Monkey)
Dec-16-25 05:00PM	Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program (PR Newswire) +7.03%
Nov-14-25 06:00AM	Inhibrx Reports Third Quarter 2025 Financial Results (PR Newswire) +6.04%
Nov-04-25 04:01PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Oct-24-25 07:40AM	Inhibrx Biosciences stock soars on chondrosarcoma Phase II victory (Clinical Trials Arena) +102.01%
04:05PM	Loading…
Oct-23-25 04:05PM	Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -10.03%
Oct-22-25 04:01PM	Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -15.99%
Aug-13-25 04:05PM	Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) +7.53%
Jul-28-25 11:11AM	Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer (Insider Monkey) +6.46%
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
May-14-25 04:05PM	Inhibrx Reports First Quarter 2025 Financial Results (PR Newswire) +10.89%
Apr-01-25 04:05PM	Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President (PR Newswire)
Mar-17-25 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
05:01PM	Loading…
Jan-21-25 05:01PM	Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer (PR Newswire) +5.19%
Jan-13-25 04:15PM	Inhibrx Biosciences Announces Loan Agreement with Oxford Finance (PR Newswire) -6.60%
Nov-14-24 04:24PM	Inhibrx Biosciences Reports Third Quarter 2024 Financial Results (PR Newswire) -7.25%
Nov-04-24 04:00PM	Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation (PR Newswire)
Sep-13-24 01:55AM	Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) (GuruFocus.com) +8.82%
Aug-13-24 06:54PM	Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (PR Newswire)
May-24-24 04:00PM	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi (PR Newswire)
May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIKING GLOBAL INVESTORS LP	10% Owner	Oct 07 '25	Sale	32.25	350,000	11,287,500	67,018	Oct 09 04:41 PM

Open in Screener

BDSX

Biodesix Inc

Feb 13 • 04:00PM ET

11.45

+0.61 5.68 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN BEAM CDNA FLGT GH EXAS QDEL TWST CRSP PACB

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-5.37	Insider Own	60.69%	Shs Outstand	7.95M	Perf Week	10.31%
Market Cap	91.09M	Forward P/E	-	EPS next Y	-2.58	Insider Trans	377.61%	Shs Float	3.13M	Perf Month	33.29%
Enterprise Value	147.32M	PEG	-	EPS next Q	-0.86	Inst Own	21.48%	Short Float	7.97%	Perf Quarter	44.03%
Income	-39.54M	P/S	1.14	EPS this Y	22.00%	Inst Trans	-3.50%	Short Ratio	0.18	Perf Half Y	44.21%
Sales	80.17M	P/B	-	EPS next Y	49.97%	ROA	-41.30%	Short Interest	0.25M	Perf YTD	68.38%
Book/sh	-0.22	P/C	5.45	EPS next 5Y	44.09%	ROE	-302.55%	52W High	20.40 -43.87%	Perf Year	-40.55%
Cash/sh	2.10	P/FCF	-	EPS past 3/5Y	40.57% 69.26%	ROIC	-56.64%	52W Low	3.44 233.24%	Perf 3Y	-69.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	9.38% 23.77%	Gross Margin	79.82%	Volatility	13.30% 15.35%	Perf 5Y	-97.69%
Dividend TTM	-	EV/Sales	1.84	EPS Y/Y TTM	31.93%	Oper. Margin	-40.35%	ATR (14)	1.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.76	Sales Y/Y TTM	22.29%	Profit Margin	-49.31%	RSI (14)	61.65	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.84	EPS Q/Q	17.13%	SMA20	10.73%	Beta	0.65	Target Price	32.50
Payout	-	Debt/Eq	-	Sales Q/Q	19.93%	SMA50	34.32%	Rel Volume	0.24	Prev Close	10.84
Employees	273	LT Debt/Eq	-	Earnings	Feb 26 AMC	SMA200	50.87%	Avg Volume	1.41M	Price	11.45
IPO	Oct 28, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	22.15% 3.79%	Trades		Volume	331,766	Change	5.68%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	William Blair	Outperform → Mkt Perform
Sep-16-24	Initiated	Scotiabank	Sector Outperform
Jul-26-24	Initiated	Craig Hallum	Buy	$3
May-13-24	Initiated	TD Cowen	Buy	$2.80
May-03-24	Initiated	Lake Street	Buy	$3
Nov-17-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$21 → $11
Nov-23-20	Initiated	William Blair	Outperform
Nov-23-20	Initiated	Morgan Stanley	Overweight	$20
Nov-23-20	Initiated	Canaccord Genuity	Buy	$26
Nov-23-20	Initiated	BTIG Research	Buy	$22

Feb-12-26 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Jan-31-26 08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-12-26 06:00AM	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) (GlobeNewswire) +47.99%
Dec-24-25 01:48PM	SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio (Zacks)
Dec-19-25 11:05AM	Cencora to Acquire OneOncology to Expand Community Oncology Solutions (Zacks) -5.77%
09:55AM	Loading…
Dec-03-25 09:55AM	Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade (Zacks)
08:22AM	Biodesix to Present New Data at Two Major Upcoming Scientific Meetings (GlobeNewswire)
Nov-04-25 12:01AM	Biodesix Inc (BDSX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Costs (GuruFocus.com) +19.87%
Nov-03-25 05:30PM	Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.17%
04:01PM	Biodesix Announces Third Quarter 2025 Results and Highlights (GlobeNewswire)
Oct-31-25 09:35AM	What To Expect From Biodesix Inc (BDSX) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 06:17AM	Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting (GlobeNewswire)
Oct-29-25 05:45PM	Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-27-25 07:10AM	Revvity (RVTY) Surpasses Q3 Earnings Estimates (Zacks)
Oct-22-25 06:17AM	Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays (GlobeNewswire) -12.15%
06:00AM	Loading…
Oct-20-25 06:00AM	Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025 (GlobeNewswire)
Oct-15-25 06:09AM	Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting (GlobeNewswire)
Oct-06-25 10:13AM	Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit (GlobeNewswire)
Sep-11-25 08:00AM	Biodesix Announces One-for-Twenty Reverse Stock Split (GlobeNewswire) -20.82%
Sep-05-25 06:00AM	Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference (GlobeNewswire)
Sep-04-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +5.05%
Aug-19-25 09:47AM	Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics (GlobeNewswire)
Aug-07-25 05:20PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +14.62% -10.40%
04:06PM	Biodesix Announces Second Quarter 2025 Results and Highlights (GlobeNewswire)
Aug-05-25 06:00AM	Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire) +10.10%
Aug-01-25 07:15AM	Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates (Zacks)
Jul-25-25 12:22PM	Biodesix, APAPP Partner to Launch First CME-Accredited Education Program for Lung Cancer Biomarkers (Insider Monkey) +6.80%
12:22PM	Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy (Insider Monkey)
Jul-24-25 06:00AM	Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jun-10-25 06:17AM	Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs (GlobeNewswire) +13.91%
05:03PM	Loading…
May-22-25 05:03PM	Biodesix Announces New Data on the VeriStrat Test to be Presented at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.92%
May-21-25 06:00AM	Biodesix to Participate in Upcoming Investor Conferences (GlobeNewswire) +45.90%
May-15-25 06:00AM	Biodesix Announces New Clinical and Economic Data for its Nodify Lung Tests at ISPOR and ATS (GlobeNewswire)
May-14-25 04:01PM	Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award (GlobeNewswire) -38.74%
03:16AM	Biodesix Inc (BDSX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Sales Team ... (GuruFocus.com)
May-13-25 05:15PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2025 Results and Highlights (GlobeNewswire)
May-12-25 09:50AM	Biodesix Inc (BDSX) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:25AM	Sonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 06:30PM	DocGo Inc. (DCGO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -17.91% +6.84%
Apr-30-25 07:45AM	GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates (Zacks)
Apr-29-25 06:00AM	Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire) -6.51%
Apr-28-25 07:15AM	Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates (Zacks) +6.25%
Apr-25-25 07:15AM	Avantor, Inc. (AVTR) Q1 Earnings Meet Estimates (Zacks) -5.64%
Apr-23-25 06:00AM	Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types (GlobeNewswire)
Mar-06-25 12:00PM	Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-04-25 05:20AM	Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025 (Insider Monkey)
02:03AM	Biodesix Inc (BDSX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Mar-03-25 04:01PM	Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results (GlobeNewswire) -10.09%
Feb-28-25 07:15AM	Biodesix Inc (BDSX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-26-25 06:00AM	Biodesix to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 (GlobeNewswire)
Jan-10-25 06:00AM	Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) (GlobeNewswire) -14.19%
Jan-07-25 06:00AM	Biodesix Announces Publication of a New Nodify CDT Clinical Validation Study (GlobeNewswire)
Nov-20-24 09:35AM	Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-02-24 03:01AM	Biodesix Inc (BDSX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... (GuruFocus.com)
Nov-01-24 07:15AM	Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -23.53%
06:00AM	Biodesix Announces Third Quarter 2024 Results and Highlights (GlobeNewswire)
Oct-31-24 09:06AM	What To Expect From Biodesix Inc (BDSX) Q3 2024 Earnings (GuruFocus.com)
Oct-29-24 06:00AM	Biodesix to Participate in Three Investor Conferences in November (GlobeNewswire)
Oct-18-24 06:00AM	Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024 (Business Wire)
Oct-07-24 06:00AM	Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study (Business Wire)
Sep-05-24 06:00AM	Biodesix to Present at Two Investor Conferences in September (Business Wire)
Aug-08-24 10:23AM	Q2 2024 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 06:05PM	Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces Second Quarter 2024 Results and Highlights (Business Wire)
Aug-06-24 06:00AM	Biodesix to Present at Canaccord Genuitys 44th Annual Growth Conference (Business Wire)
Jul-24-24 06:00AM	Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024 (Business Wire)
Jun-18-24 08:13AM	Biodesix Named to Inc. Magazine's 2024 "Best Workplaces" (Business Wire)
May-28-24 06:00AM	Biodesix to Participate in Two Investor Conferences in June (Business Wire)
May-21-24 06:00AM	Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting (Business Wire)
May-10-24 05:59PM	Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:55PM	Biodesix Inc (BDSX) Surpasses Analyst Revenue Forecasts with Strong Q1 2024 Performance (GuruFocus.com)
May-09-24 03:46AM	Biodesix Inc (BDSX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-08-24 09:00PM	BDSX Stock Earnings: Biodesix Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:20PM	Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management (Business Wire)
May-07-24 06:00AM	Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference (Business Wire)
Apr-24-24 06:00AM	Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-09-24 05:00PM	Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting (Business Wire) -9.93%
Apr-05-24 07:17AM	Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement (Business Wire) -7.28%
Mar-25-24 06:00AM	Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center (Business Wire)
Mar-04-24 09:04AM	Biodesix, Inc. (NASDAQ:BDSX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 10:40PM	Q4 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)
06:31AM	Biodesix Inc (BDSX) Reports Strong Growth in Lung Diagnostic Test Volume and Gross Profit Margin (GuruFocus.com)
06:00AM	Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights (Business Wire)
Feb-26-24 06:00AM	Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-16-24 06:00AM	Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024 (Business Wire) -5.73%
Feb-13-24 03:00AM	Biodesix Inc CEO Scott Hutton Sells 64,390 Shares (GuruFocus.com)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Nov-14-23 06:00AM	Biodesix Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method (Business Wire)
Nov-09-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in November (Business Wire) -6.39%
Nov-07-23 04:01PM	Biodesix Announces Third Quarter 2023 Results and Highlights (Business Wire) -10.14%
Oct-24-23 06:00AM	Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire) -5.00%
Oct-03-23 06:00AM	Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting (Business Wire)
Sep-07-23 06:00AM	Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer (Business Wire)
Sep-05-23 06:00AM	Biodesix to Participate in Two Upcoming Investor Conferences in September (Business Wire) -11.76%
Aug-22-23 06:00AM	Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer (Business Wire)
Aug-09-23 10:25AM	Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript (Insider Monkey) -15.62%
Aug-08-23 08:38AM	Q2 2023 Biodesix Inc Earnings Call (Thomson Reuters StreetEvents)

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Kane Kieran	Chief Commercial Officer	Feb 10 '26	Sale	10.08	584	5,889	8,885	Feb 11 06:03 PM
Vazquez Chris	Chief Accounting Officer	Feb 10 '26	Sale	10.08	101	1,018	1,234	Feb 11 06:03 PM
Hutton Scott	President & CEO	Feb 10 '26	Sale	10.08	3,559	35,889	45,413	Feb 11 06:03 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Feb 10 '26	Sale	10.08	941	9,489	15,297	Feb 11 06:03 PM
Pestano Gary Anthony	Chief Development Officer	Feb 10 '26	Sale	10.08	540	5,445	9,387	Feb 11 06:03 PM
SCHULER JACK W	Emeritus Director	Jan 23 '26	Buy	11.81	80,000	944,672	1,543,210	Jan 27 09:29 AM
SCHULER JACK W	Emeritus Director	Jan 26 '26	Buy	11.80	20,000	236,064	1,563,210	Jan 27 09:29 AM
SCHULER JACK W	Emeritus Director	Jan 22 '26	Buy	10.96	82,465	903,561	1,463,210	Jan 26 09:28 AM
Vazquez Chris	Chief Accounting Officer	Jan 16 '26	Sale	8.15	83	676	1,072	Jan 20 04:22 PM
Pestano Gary Anthony	Chief Development Officer	Jan 16 '26	Sale	8.15	298	2,428	8,446	Jan 20 04:21 PM
O'Kane Kieran	Chief Commercial Officer	Jan 16 '26	Sale	8.15	298	2,428	7,869	Jan 20 04:21 PM
Hutton Scott	President & CEO	Jan 16 '26	Sale	8.15	970	7,905	38,974	Jan 20 04:21 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Jan 16 '26	Sale	8.15	298	2,428	13,654	Jan 20 04:21 PM
Vazquez Chris	Chief Accounting Officer	Nov 10 '25	Sale	7.62	13	99	936	Nov 13 04:54 PM
Pestano Gary Anthony	Chief Development Officer	Nov 10 '25	Sale	7.62	23	175	7,939	Nov 13 04:54 PM
O'Kane Kieran	Chief Commercial Officer	Nov 10 '25	Sale	7.62	25	190	7,362	Nov 13 04:53 PM
Hutton Scott	President & CEO	Nov 10 '25	Sale	7.62	189	1,440	37,311	Nov 13 04:53 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Nov 10 '25	Sale	7.62	50	381	13,147	Nov 13 04:53 PM
SCHULER JACK W	Director	Sep 19 '25	Buy	7.04	142,045	999,997	1,380,745	Sep 23 09:29 AM
SCHULER JACK W	Director	Sep 17 '25	Buy	6.04	15,317	92,571	1,235,644	Sep 19 10:31 AM
SCHULER JACK W	Director	Sep 18 '25	Buy	6.17	3,056	18,854	1,238,700	Sep 19 10:31 AM
SCHULER JACK W	Director	Aug 29 '25	Buy	0.43	3,488,372	1,500,000	24,406,546	Sep 03 04:42 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	Aug 13 '25	Sale	0.42	988	411	250,794	Aug 14 05:25 PM
Hutton Scott	President & CEO	Aug 13 '25	Sale	0.42	3,772	1,570	728,824	Aug 14 05:25 PM
O'Kane Kieran	Chief Commercial Officer	Aug 13 '25	Sale	0.42	476	198	140,065	Aug 14 05:24 PM
Pestano Gary Anthony	Chief Development Officer	Aug 13 '25	Sale	0.42	442	184	157,878	Aug 14 05:24 PM
Vazquez Chris	Chief Accounting Officer	Aug 13 '25	Sale	0.42	228	95	18,375	Aug 14 05:24 PM
SCHULER JACK W	Director	May 16 '25	Buy	0.27	4,000,000	1,070,000	20,194,935	May 20 04:11 PM
SCHULER JACK W	Director	May 19 '25	Buy	0.34	723,239	246,624	20,918,174	May 20 04:11 PM
Vazquez Chris	Chief Accounting Officer	May 12 '25	Sale	0.36	112	40	18,113	May 13 06:36 PM
Vazquez Chris	Chief Accounting Officer	May 13 '25	Sale	0.35	112	40	18,001	May 13 06:36 PM
Pestano Gary Anthony	Chief Development Officer	May 12 '25	Sale	0.36	223	80	157,163	May 13 06:36 PM
Pestano Gary Anthony	Chief Development Officer	May 13 '25	Sale	0.35	222	78	156,941	May 13 06:36 PM
O'Kane Kieran	Chief Commercial Officer	May 12 '25	Sale	0.36	239	86	139,290	May 13 06:35 PM
O'Kane Kieran	Chief Commercial Officer	May 13 '25	Sale	0.35	238	84	139,052	May 13 06:35 PM
Hutton Scott	President & CEO	May 12 '25	Sale	0.36	1,888	679	722,271	May 13 06:35 PM
Hutton Scott	President & CEO	May 13 '25	Sale	0.35	1,887	666	720,384	May 13 06:35 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 12 '25	Sale	0.36	496	178	249,121	May 13 06:35 PM
Cowie Robin Harper	CFO, Sec'y & Treasurer	May 13 '25	Sale	0.35	496	175	248,625	May 13 06:35 PM

INBX

Inhibrx Biosciences Inc

BDSX

Biodesix Inc

Upgrade your FINVIZ experience